Rituximab/Bendamustine + Rituximab/Cytarabine for Mantle Cell Lymphoma

This was a PII single-arm design to determine whether the regimen looked promising for further study. Primary Objective • To evaluate the efficacy of an alternating regimen of Rituximab-Bendamustine and Rituximab-Cytarabine (RB/RC) using the CR/Cru rate. Secondary Objectives * To assess safety. * To estimate the rate of complete remission (CR), unconfirmed CR (CRu), partial remission (PR), stable disease (SD) and progressive disease (PD). * To estimate the rate of successful stem cell mobilization after RB/RC in responding patients. * To estimate the proportion of patients who can successfully complete the regimen and proceed to autologous stem cell transplantation (ASCT). * To estimate the rate of neutrophil and platelet engraftment after ASCT. * To estimate the CR/CRu and PR rate for patients with blastoid variant MCL. * To estimate the rate of minimal residual disease (MRD)-negativity at treatment completion.